BenzingaOctober 2, 2026 at 2:46 AM NY25 Days Ago
Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and maintains $40 price target.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
